• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

    6/26/25 7:55:49 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email

    MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule").

    On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied the requirements of the Equity Rule. On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). Therefore, the Company now meets all Nasdaq Capital Market listing requirements for continued listing, and these matters are closed.

    About HCW Biologics:

    HCW Biologics Inc. (NASDAQ:HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients' quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using the Company's legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/

    Company Contact:

    Rebecca Byam

    CFO

    HCW Biologics Inc.

    [email protected]



    Primary Logo

    Get the next $HCWB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    SEC Filings

    See more
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      7/1/25 8:30:29 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      6/26/25 8:00:29 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      6/23/25 4:40:38 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on HCW Biologics with a new price target

      EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

      11/19/21 8:39:08 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

      Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Instituteon June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have success

      6/27/25 7:45:56 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

      MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied

      6/26/25 7:55:49 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

      MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitmen

      6/4/25 8:20:19 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Financials

    Live finance-specific insights

    See more
    • HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

      MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a

      8/12/22 7:00:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

      MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica

      5/13/22 7:15:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    See more
    • HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

      MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

      4/1/24 4:10:32 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

      SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

      11/22/24 4:53:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care